According to the National Centre for Advancing Translational Sciences” Giant-Cell Arteritis (GCA, also known as Temporal arteritis; Cranial Arteritis; Granulomatous Arteritis and Horton’s disease) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow”.
The signs and symptoms of Giant Cell Arteritis are tenderness of the scalp, flu-like symptoms, problems with eyesight, and throbbing headache on one side or the back of the head. This happens when arteries in the head are involved.
Get FREE sample copy at:
The Giant-Cell Arteritis market report also covers emerging drugs, current treatment practices, Giant-Cell Arteritis market share of the individual therapies, current and forecasted Giant-Cell Arteritis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Giant-Cell Arteritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Giant-Cell Arteritis Market Key Facts
According to the data of the Arthritis Foundation, Caucasian women over the age of 50 (most commonly between the ages of 70 and 80 years), have the highest risk of developing Giant-Cell Arteritis. Although women are more likely than men to develop GCA, research suggests that men are more likely to suffer potentially blinding eye involvement.
Giant-Cell Arteritis occurs most frequently in populations of Northern Europe, and in particular in Scandinavian countries where the incidence has been reported as high as 32.8 per 100,000 inhabitants over the age of 50 years.
According to the National Organization for Rare Diseases (NORD,), Giant-Cell Arteritis occurs in approximately 24 in 100,000 people over the age of 50 years, affecting twice as many females as males. Also, GCA affects 110,000 individuals in the United States.
According to Ness et al. (2013) in an article titled “The Diagnosis and Treatment of Giant Cell Arteritis”, the incidence of GCA in Europe showed a marked north-south divide. In Germany, the incidence is stable at 3.5 per 100 000 inhabitants per year in the over-50 age group. Women are affected two to six times as often as men. After the age of 50, the incidence increases with age.
Key Benefits of Giant-Cell Arteritis Market Report
Giant-Cell Arteritis market report provides an in-depth analysis of Giant-Cell Arteritis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Giant-Cell Arteritis market report will help in developing business strategies by understanding the Giant-Cell Arteritis Market trends & developments, key players and future market competition that will shape and drive the Giant-Cell Arteritis market in the upcoming years.
The Giant-Cell Arteritis market report covers Giant-Cell Arteritis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Giant-Cell Arteritis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Giant-Cell Arteritis Market
The market size of Giant Cell Arteritis is expected to grow during the forecast period owing to the launch of upcoming therapies.
The Giant-Cell Arteritis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Giant-Cell Arteritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Giant-Cell Arteritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Giant-Cell Arteritis Epidemiology
The Giant-Cell Arteritis epidemiology section covers insights about historical and current Giant-Cell Arteritis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted Giant-Cell Arteritis trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Giant-Cell Arteritis Drugs Uptake and Key Market Players
The Giant-Cell Arteritis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant-Cell Arteritis market or expected to get launched in the market during the study period. The analysis covers Giant-Cell Arteritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Giant-Cell Arteritis market is anticipated to change in the coming years, owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period.
Some of the Key Companies in Giant Cell Arteritis Market Include:
Giant Cell Arteritis Therapies Covered
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Giant-Cell Arteritis Competitive Intelligence Analysis
4. Giant-Cell Arteritis Market Overview at a Glance
5. Giant-Cell Arteritis Disease Background and Overview
6. Giant-Cell Arteritis Patient Journey
7. Giant-Cell Arteritis Epidemiology and Patient Population
8. Giant-Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Giant-Cell Arteritis Unmet Needs
10. Key Endpoints of Giant-Cell Arteritis Treatment
11. Giant-Cell Arteritis Marketed Products
12. Giant-Cell Arteritis Emerging Therapies
13. Giant-Cell Arteritis Seven Major Market Analysis
14. Attribute Analysis
15. Giant-Cell Arteritis Market Outlook (7 major markets)
16. Giant-Cell Arteritis Access and Reimbursement Overview
17. KOL Views on the Giant-Cell Arteritis Market.
18. Giant-Cell Arteritis Market Drivers
19. Giant-Cell Arteritis Market Barriers
21. DelveInsight Capabilities
Giant Cell Arteritis (GCA) – Epidemiology Forecast to 2030
DelveInsight’s Giant Cell Arteritis (GCA) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Giant Cell Arteritis (GCA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Giant-Cell Arteritis – Pipeline Insights, 2020
Giant-Cell Arteritis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Giant-Cell Arteritis market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd 2432
City: Las Vegas
Country: United States